- Home
- CEV vs IMAB Comparison
CEV vs IMAB Comparison
Compare CEV & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEV
- IMAB
- Stock Information
- Founded
- CEV 1999
- IMAB 2014
- Country
- CEV United States
- IMAB United States
- Employees
- CEV N/A
- IMAB N/A
- Industry
- CEV Finance/Investors Services
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- CEV Finance
- IMAB Health Care
- Exchange
- CEV Nasdaq
- IMAB Nasdaq
- Market Cap
- CEV 71.8M
- IMAB 73.9M
- IPO Year
- CEV N/A
- IMAB 2020
- Fundamental
- Price
- CEV $9.62
- IMAB $0.85
- Analyst Decision
- CEV
- IMAB Strong Buy
- Analyst Count
- CEV 0
- IMAB 2
- Target Price
- CEV N/A
- IMAB $5.50
- AVG Volume (30 Days)
- CEV 19.6K
- IMAB 261.6K
- Earning Date
- CEV 01-01-0001
- IMAB 04-03-2025
- Dividend Yield
- CEV 4.23%
- IMAB N/A
- EPS Growth
- CEV N/A
- IMAB N/A
- EPS
- CEV 0.36
- IMAB N/A
- Revenue
- CEV N/A
- IMAB N/A
- Revenue This Year
- CEV N/A
- IMAB N/A
- Revenue Next Year
- CEV N/A
- IMAB N/A
- P/E Ratio
- CEV $29.36
- IMAB N/A
- Revenue Growth
- CEV N/A
- IMAB N/A
- 52 Week Low
- CEV $8.83
- IMAB $0.60
- 52 Week High
- CEV $10.91
- IMAB $2.00
- Technical
- Relative Strength Index (RSI)
- CEV 36.08
- IMAB 53.01
- Support Level
- CEV $9.31
- IMAB $0.63
- Resistance Level
- CEV $10.19
- IMAB $1.01
- Average True Range (ATR)
- CEV 0.13
- IMAB 0.10
- MACD
- CEV -0.03
- IMAB 0.02
- Stochastic Oscillator
- CEV 35.23
- IMAB 60.39
About CEV Eaton Vance California Municipal Income Trust Shares of Beneficial Interest
Eaton Vance CA Muni Income Trust is a non-diversified closed-end investment company. The company's investment objective is to provide current income exempt from regular federal income tax and California state personal income taxes. It invests in municipal obligations, issued by the State of California or its political subdivisions, agencies, authorities and instrumentalities and also has some exposure to corporate bonds.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).